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Purpose of the study
Darunavir (DRV) is a second generation protease inhibi-
tor (PI), first licensed for use in 2006. It is indicated for
use in a treatment experienced population and is effec-
tive in vitro against both wild type and PI-resistant HIV.
As a relatively new drug there is little published infor-
mation on the pharmacokinetics of darunavir in preg-
nancy. Here we examine the pharmacokinetics of
darunavir/ritonavir [DRV/r 800/100mg once daily (OD)]
in two women, over the course of pregnancy and
postpartum.
Methods
A prospective open labelled study was established to
enrol HIV positive pregnant women on DRV/r as part
of their routine maternity care. DRV plasma trough con-
centrations were determined in the first (T1) and/or sec-
ond (T2) and/or third (T3) trimester using a validated
HPLC-MS/MS methodology with a limit quantification
of 16 ng/ml. Postpartum (PP) sampling was also
performed.
Summary of results
To date two women have been recruited. Both were
black African and initiated treatment prior to pregnancy.
Each woman was virally suppressed (HIV RNA <50
cpm) throughout pregnancy and had CD4 cell counts
>300 cells/mm
3 (range 341-470). Patient 1 had a TDM
sample drawn in each trimester and at PP. DRV concen-
trations in T1 [3790ng/ml], T2 [1285ng/ml] and T3
[1773ng/ml] were considerably (27-75%) lower relative
to concentrations at PP [5227ng/ml]. Patient 2 had
TDM samples taken in T2 and PP only. Again a consid-
erably lower (~72%) DRV concentration was noted at
T2 compared with PP. In both cases, DRV concentra-
tions in pregnancy and postpartum were above the
accepted minimum effective concentration for wt virus
(MEC; 550 ng/ml, based on in vitro studies).
Conclusions
In the two cases examined, DRV/r (800/100mg, OD)
was effective at achieving adequate therapeutic drug
levels (>550ng/ml) during pregnancy. However, reduced
DRV plasma concentrations in the second/third trime-
sters, highlights the need for TDM in this population,
and warrants further study of pregnancy-associated
changes in DRV pharmacokinetics.
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